Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization
Detection of both low-risk (6, 11) and high-risk genotypes (16, 18, 31, 33, and 51) of human papillomavirus DNA in paraffin-embedded human tissue
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
Human papillomavirus (HPV) high-risk E6/E7 will be performed at the discretion of the Mayo pathologist.
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Human papillomavirus (HPV) infections with low-risk genotypes (6, 11) can cause benign hyperplasia such as condylomas and papillomas. Persistent infections with high-risk genotypes (16, 18, 31, 33, and 51) are associated with cervical, vaginal, vulvar, and head and neck malignancies. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) have shown better disease-specific survival and overall survival when compared to HPV-negative cases of OPSCC.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Results are reported as positive or negative for low-risk genotypes 6, 11, and/or high-risk genotypes 16, 18, 31, 33, and 51.
If additional interpretation or analysis is needed, request 70012 / Pathology Consultation along with this test.
This test, when not accompanied by a pathology consultation request, will be answered as either positive or negative. If additional interpretation or analysis is needed, request 70012 / Pathology Consultation along with this test.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
The probe set used in this human papillomavirus (HPV) DNA in situ hybridization (ISH) test cannot detect all potential HPV serotypes that are associated with oropharyngeal squamous cell carcinoma. Following a negative DNA ISH result, a more sensitive in situ RNA test (62886 / Human Papillomavirus (HPV) High Risk E6/E7, RNA In Situ Hybridization) may be performed, if clinically indicated, at the discretion of the Mayo pathologist.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Kelesidis T, Aish L, Steller MA, et al: Human papillomavirus (HPV) detection using in situ hybridization in histologic samples. Am J Clin Pathol 2011;136:119-127
2. Lee WT, Tubbs RR, Teker AM, et al: Use of in situ hybridization to detect human papillomavirus in head and neck squamous cell carcinoma patients without a history of alcohol or tobacco use. Arch Pathol Lab Med 2008;132:1653-1656
3. Birner P, Bachtiary B, Dreier B, et al: Signal-amplified colorimetric in situ hybridization for assessment of human papillomavirus infection in cervical lesions. Mod Pathol 2001;14(7):702-709